Defeating MYC with drug combinations or dual-targeting drugs
Author(s)
Thompson, PE; Shortt, J;
Details
Publication Year 2024-06,Volume 45,Issue #6,Page 490-502
Journal Title
Trends in Pharmacological Sciences
Publication Type
Review
Abstract
Members of the MYC family of proteins are a major target for cancer drug discovery, but the development of drugs that block MYC-driven cancers has not yet been successful. Approaches to achieve success may include the development of combination therapies or dual-acting drugs that target MYC at multiple nodes. Such treatments hold the possibility of additive or synergistic activity, potentially reducing side effect profiles and the emergence of resistance. In this review, we examine the prominent MYC-related targets and highlight those that have been targeted in combination and/or dual-target approaches. Finally, we explore the challenges of combination and dual-target approaches from a drug development perspective.
Publisher
Cell Press
Keywords
Humans; *Neoplasms/drug therapy; *Proto-Oncogene Proteins c-myc/genetics/metabolism/antagonists & inhibitors; *Antineoplastic Agents/pharmacology; Animals; Molecular Targeted Therapy; Antineoplastic Combined Chemotherapy Protocols/pharmacology; Myc; anti-cancer drug discovery; combination therapies; dual target drugs
Department(s)
Clinical Haematology
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2024-08-27 07:14:39
Last Modified: 2024-08-27 07:28:18

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙